Indoco Remedies Limited (INDOCO) Fair Value & Analysis
Healthcare · IN · Market cap ₹22.5B
Fair value as of: Jul 3, 2026
From 8 valuation models · updated yesterday
Share price +17.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹164.01 – ₹338.89 · fair‑value band ₹46.88 – ₹154.57 · the ₹244.02 price screens above the ₹100.73 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Indoco Remedies Limited (INDOCO) currently trades at ₹244.02, while our model-based Fair Value estimate is ₹100.73 — implying the stock looks roughly 58.7% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Indoco Remedies Limited generated revenue of ₹18.5B at a net margin of -5.2%. Revenue grew 21.9% year over year. It earns a return on equity of -10.1%. Net debt stands at ₹10.6B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Indoco Remedies Limited reported revenue of ₹18.5B in FY2026 versus ₹15.0B in FY2022, a compound +5.3%/yr. Reported net income was −₹987M in FY2026.
Is INDOCO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Indoco Remedies Limited (INDOCO) undervalued?
What is the fair value of INDOCO?
What is the quality score of INDOCO?
What is the revenue of Indoco Remedies Limited (INDOCO)?
What is the net profit margin of INDOCO?
Does Indoco Remedies Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.